Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus cetuximab for unresectable cutaneous squamous cell carcinoma
2018-001708-12Phase 2Completed
- Sponsor
- Alcedis
- Start
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and cetuximab in cutaneous squamous cell carcinoma (cSCC), sponsored by Alcedis. Primary endpoint: Objective response rate. Started Sep 2018; status: completed.
02
Drugs
avelumabcetuximab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2018-001708-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001708-12.